Aminopeptidase P in individuals with a history of angio-oedema on ACE inhibitors.
Angio-oedema is a rare but potentially life threatening side-effect of angiotensin-converting-enzyme (ACE) inhibitor treatment. Identification of individuals at risk of this adverse effect is not possible. Angio-oedema is associated with raised concentrations of bradykinin, which is mainly inactivated by ACE. We assessed the plasma activity of two other enzymes that catabolise bradykinin (aminopeptidase P and carboxypeptidase N) in 39 hypertensive patients with a history of angio-oedema during ACE inhibitor treatment and in 39 hypertensive patients who had never had ACE inhibitor associated side-effects. Patients with previous angio-oedema had a lower plasma activity of aminopeptidase P than did those who never presented with angio-oedema (p=0 003). Our data suggest that low plasma concentrations of aminopeptidase P could be a predisposing factor for development of angio-oedema in patients treated with ACE inhibitors.
Adam
Albert
A
Faculté de Pharmacie, Université de Montréal, Montréal, Canada. albert.adams@umontreal.ca
Cugno
Massimo
M
Molinaro
Giuseppe
G
Perez
Melissa
M
Lepage
Yves
Y
Agostoni
Angelo
A
D000328:Adult; D000368:Aged; D000626:Aminopeptidases / Q000097:blood*; D000704:Analysis of Variance; D000799:Angioedema / Q000097:blood / Q000139:chemically induced* / Q000201:enzymology; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000009:adverse effects*; D016022:Case-Control Studies; D006801:Humans; D006973:Hypertension / Q000188:drug therapy; D001121:Lysine Carboxypeptidase / Q000097:blood*; D008875:Middle Aged
D000806:Angiotensin-Converting Enzyme Inhibitors; D000626:Aminopeptidases; C022750:X-Pro aminopeptidase; D001121:Lysine Carboxypeptidase